Transcatheter heart valve for aortic valve implantation: republication of the article published in the Japanese Journal of Artificial Organs
Review Artificial Valve
This review was created based on a translation of the Japanese review first reported in the Japanese Journal of Artificial Organs in 2015 (vol. 44, no. 3, pp. 136–140), with some modifications.
KeywordsTranscatheter heart valve (THV) Transcatheter aortic valve implantation (TAVI) Balloon-expandable valve (BEV) Self-expandable valve (SEV)
Compliance with ethical standards
Conflict of interest
The author has no COIs.
- 9.Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84.CrossRefPubMedGoogle Scholar
- 16.Watanabe Y, Hayashida K, Takayama M, Mitsudo K, Nanto S, Takanashi S. et.al. First direct comparison of clinical outcomes between European and Asian cohorts in transcatheter aortic valve implantation: the Massy study group vs. the PREVAIL JAPAN trial. J Cardiol. 2015;65:112–6.CrossRefPubMedGoogle Scholar
- 17.Mizutani K, Hara M, Iwata S, Murakami T, Shibata T, Hayashida K, et al. Elevation of B-type natriuretic peptide at discharge is associated with 2-year mortality after transcatheter aortic valve replacement in patients with severe aortic stenosis: insights from a multicenter prospective OCEAN-TAVI (optimized transcatheter valvular intervention-transcatheter aortic valve implantation) registry. J Am Heart Assoc. 2017;6:1–10.CrossRefGoogle Scholar
© The Japanese Society for Artificial Organs 2018